Scholar Rock Holding Corp
NASDAQ:SRRK
Intrinsic Value
Scholar Rock Holding Corp. is a biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SRRK.
Scholar Rock Holding Corp's market capitalization is 1.1B USD.
SRRK stock price is 14.79 USD.
SRRK.
SRRK. Open DCF Valuation
SRRK. Open Relative Valuation
SRRK has upside potential of 81% compared to the average analyst price target.
Open Wall St Estimates
SRRK's ROE (Return on Equity) has significantly decreased in the last 3 years from -57% to -68%, and is approaching profitability.
SRRK's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -341% to -516%, and is approaching profitability.
SRRK has negative Operating Income for the last twelve months.
SRRK has negative Net Income for the last twelve months.
SRRK's ROE (Return on Equity) for the past 12 months is negative and is equal to -68%.
SRRK's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -516%.
SRRK has negative Free Cash Flow for the last twelve months.
SRRK's D/E (Debt to Equity) is very low and is equal to 0.22.
SRRK's long-term assets (311m USD) exceed its long-term liabilties (86m USD).
SRRK has negative three-year average ROE (Return on Equity): -64%. The company is not efficient at transforming stockholders' equity into net income.
SRRK has negative three-year average ROIC (Return on Invested Capital): -325%. The company is not efficient at using invested capital to generate operating income.
SRRK's short-term assets (288m USD) exceed its short-term liabilties (33m USD).
SRRK has negative Net Debt. This means that the company has more cash and short-term investments (280m USD) than debt (50m USD).
SRRK's Altman Z-Score is very high and is equal to 5.04.
SRRK doesn't generate enough operating income (-171m USD) to safely cover interest payments on its debt (6m USD).
Fundamental Analysis
Scholar Rock Holding Corp
Balance Sheet Decomposition
Scholar Rock Holding Corp
| Current Assets | 288.2m |
| Cash & Short-Term Investments | 279.9m |
| Other Current Assets | 8.3m |
| Non-Current Assets | 22.8m |
| PP&E | 16m |
| Other Non-Current Assets | 6.8m |
| Current Liabilities | 32.7m |
| Accounts Payable | 3.5m |
| Accrued Liabilities | 27.9m |
| Short-Term Debt | 1.3m |
| Other Current Liabilities | 85k |
| Non-Current Liabilities | 53.1m |
| Long-Term Debt | 48.7m |
| Other Non-Current Liabilities | 4.4m |
Earnings Waterfall
Scholar Rock Holding Corp
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-171.3m
USD
|
|
Operating Income
|
-171.3m
USD
|
|
Other Expenses
|
5.5m
USD
|
|
Net Income
|
-165.8m
USD
|
Free Cash Flow Analysis
Scholar Rock Holding Corp
SRRK Profitability Score
Profitability Due Diligence
Scholar Rock Holding Corp's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Scholar Rock Holding Corp's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
SRRK Solvency Score
Solvency Due Diligence
Scholar Rock Holding Corp's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Scholar Rock Holding Corp's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRRK Price Targets Summary
Scholar Rock Holding Corp
According to Wall Street analysts, the average 1-year price target for
SRRK
is 26.78 USD
with a low forecast of 20.2 USD and a high forecast of 31.5 USD.
Ownership
SRRK Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SRRK Price
Scholar Rock Holding Corp
| Average Annual Return | 35.94% |
| Standard Deviation of Annual Returns | 166.19% |
| Max Drawdown | -93% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 77 866 304 |
| Percentage of Shares Shorted | 29.81% |
Company Profile
Scholar Rock Holding Corp
Country
Industry
Market Cap
Dividend Yield
Description
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2018-05-24. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFβ1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. Its selective inhibitors of the activation of transforming growth factor-beta (TGFβ) for the treatment of fibrotic diseases. The company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFβ1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFβ1 presented by cells of the immune system.
You don't have any saved screeners yet
